期刊
CANCER CHEMOTHERAPY AND PHARMACOLOGY
卷 65, 期 5, 页码 903-911出版社
SPRINGER
DOI: 10.1007/s00280-009-1097-3
关键词
AP-1; Celecoxib; COX-2; HepG2 cells; MDR1; Simulation
资金
- Council of Scientific and Industrial Research (CSIR) [37(1221)/05/EMR-II]
- Department of Science and Technology (DST) [VII-PRDSF/50/05-06/TDT]
- University Grants Commission (UGC), New Delhi
- DBT, Govt. of India
The role of COX-2 in the regulation of the expression of MDR1, a P-glycoprotein involved in hepatocellular carcinoma cell line, HepG2, was studied in the present investigation. Celecoxib, a selective inhibitor of COX-2, at 25 mu M concentration increased the accumulation of doxorubicin in HepG2 cells and enhanced the sensitivity of the cells to doxorubicin by tenfold. The induction of MDR1 expression by PGE(2) and its downregulation by celecoxib or by COX-2 knockdown suggests that the enhanced sensitivity of HepG2 cells to doxorubicin by celecoxib is mediated by the downregulation of MDR1 expression, through COX-2-dependent mechanism. Further studies revealed the involvement of AP-1 in the celecoxib-induced downregulation of MDR1 expression. These experimental studies correlated well with in silico predictions and further suggested the inactivation of the signal transduction pathways involving ERK, JNK and p38. The present study thus demonstrates the usefulness of COX-2 intervention in overcoming the drug resistance in HepG2 cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据